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Abstract
Background: The implementation of an integrated molecular surveillance (IMS) of tuberculosis (TB) is of high
priority for TB control. IMS is defined as the systematic inclusion of molecular typing results in the national TB
surveillance system. Although not standardized, an IMS of TB is already implemented in several low TB incidence
countries. Germany is in the process of implementing a nationwide IMS of TB. This requires close collaboration
between national and local health authorities. We conducted an online survey to understand the current use of
molecular typing results for TB surveillance among the local public health offices (PHO)s in Germany, and to collect
their perception and expectations towards the implementation of a nationwide IMS of TB.
Methods: The online survey was developed using the software Voxco and included 31 questions. The survey was
sent to all the 377 local PHOs in Germany in April 2017. Responses were collected until June 2017.
Results: A total of 174/377 (46.2%) local PHOs participated in our survey, and 88/377 (23.3%) used molecular typing
results in their routine TB surveillance work. The PHOs used molecular typing results especially as support for
epidemiological contact tracing (62/88, 70.4%). We found statistically significant differences between answers of
PHOs that did not use molecular typing results (n = 86) vs. PHOs that did use molecular typing results (n = 88): the
latter perceived the use of molecular typing results as more beneficial for their work compared to the former (65.
9% vs. 34.9%, p < 0.05). Moreover, the PHOs using molecular typing results expect for the future more support and
coordination from regional and national public health institutes, especially regarding the identification and analysis
of molecular clusters.
Conclusions: Our study is a step forward in the broader goal of implementing an IMS of TB in Germany. The local
PHOs currently using the molecular typing results highlighted their positive attitude towards the implementation of
an IMS, but also their needs of more support. Similar assessments might serve as an example for other countries
which are on the way to implement a nationwide IMS of TB.
Keywords: Tuberculosis, Molecular surveillance, Epidemiology, Public health, Molecular typing, Mycobacterium
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Background
According to public health institutes in Europe, the
implementation of a nationwide integrated molecular
surveillance (IMS) is of high priority to improve tuber-
culosis (TB) control [1]. The IMS is defined as the sys-
tematic and automatic inclusion of molecular typing
results in the national TB surveillance system. In other
words, it means combining the molecular typing results
of the Mycobacterium tuberculosis (MTB) isolate (such
as genetic lineage or drug-resistance determinants) with
epidemiological data of TB patients (such as demograph-
ics or contacts) [2, 3]. The combination of molecular
typing results–especially by using whole genome sequen-
cing (WGS)–with epidemiological data, demonstrated
several benefits for TB surveillance and control, such as in-
ferring or excluding transmission during outbreaks [4–6],
distinguishing between relapses/reinfection [7, 8], distin-
guishing between primary/acquired drug resistance [9],
evaluating TB control strategies [10] and understanding
TB epidemiology [11].
A nationwide IMS of TB, although not standardized, is
implemented in few countries such as Denmark [12],
England [13], Finland [14], the Netherlands [15],
Slovenia [16], Sweden [17] and the United States [18].
Germany is in the process of implementing IMS of TB.
In the past years, several studies have been done in
Germany in the context of molecular surveillance of TB.
However, all these studies have been conducted at the
local level (for example in one or two German federal
states), were restricted in time and used different molecu-
lar typing methods. For example, in a study conducted in
2003–2005 in the federal state of Baden-Württemberg,
molecular typing results (obtained using IS6110 DNA
fingerprinting and spoligotyping) and the conventional
contact tracing information were used to estimate TB
transmission in Germany between people with and with-
out a migration background. The results showed that
there was no transmission of TB between immigrants
originally from high TB prevalence countries and the na-
tive population with low TB prevalence [19]. Andrés and
co-authors conducted a pilot project in 2008–2010 in the
federal state of Baden-Württemberg on the systematic
integration of molecular typing results (coming from the
National Reference Center for Mycobacteria) in the na-
tional TB surveillance system. All 923 culture-positive
isolates from Baden-Württemberg were typed using
the IS6110 DNA fingerprinting. In 11% of the isolates
belonging to a molecular cluster, the molecular typing
results identified a link in absence of any epidemio-
logical link. The results of this pilot demonstrated the
feasibility and the usefulness of an IMS of TB at a
local level [20]. In another study conducted in 2006–
2010 in the federal state of Schleswig-Holstein, the
authors compared the discriminatory power of three
different molecular typing methods for TB, such as
IS6110 DNA fingerprinting, spoligotyping and 24-loci
mycobacterial interspersed repetitive units (MIRU).
The study revealed that in 93.1% of the cases there
was concordance among the results and the clustering
among these methods [21]. In a longitudinal molecu-
lar epidemiology study conducted from 1997 to 2010
in the federal state of Schleswig-Holstein and in the
city of Hamburg, researchers compared WGS and
other typing methods in analysing an outbreak (86
isolates). The WGS identified seven clusters and 36
unique isolates and demonstrated that five isolates
were wrongly included in a cluster by the other typ-
ing methods [5]. Fiebig and co-authors investigated in
2014 an international cluster of multidrug-resistant
TB spread in Austria, Romania and Germany. Ten
isolates were included in one cluster according to the
MIRU typing method, however, the WGS further di-
vided these 10 isolates into 2 subgroups, suggesting
the presence of two distinct transmission events [22].
Such local studies conducted in Germany can be seen
as “building blocks” for the preparation of a nationwide
IMS of TB. The implementation of a nationwide IMS of
TB is a public health intervention which requires a close
collaboration between several players, such as the Robert
Koch Institute (RKI, the German national public health
institute) acting as coordinator, the regional and local
public health offices (PHO)s which collect and trans-
mit the epidemiological data, the laboratories per-
forming the molecular typing and the clinical services
which communicate with both health authorities and
laboratories.
In this study, we focussed on the perspective of the
local PHOs in Germany. We conducted an online survey
among the local PHOs in Germany to understand their
current use of molecular typing results in their routine
TB surveillance work, and also their perception and ex-
pectations regarding the implementation of a nationwide
IMS of TB. At the time of this study, the use of the mo-
lecular typing result was not routinely used and could
not be reported. This situation has changed with the
amendment of the German infection protection law
(paragraphs 9 and 11 of the Infektionsschutzgesetz, IfSG)
on July 2017; available results of molecular typing now
need to be included in the notification. In addition, we
wanted to see if there was any difference in perception
and expectations on the implementation of the IMS of
TB between the PHOs belonging to the federal state of
Baden-Württemberg–which participated in the pilot
study on the implementation of the IMS of TB [20] –
and all the other PHOs. Lastly, we investigated if percep-
tion and expectations changed over time, by comparing
PHOs using molecular typing results recently (up to
2016) and in the previous years.
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Methods
Survey development and distribution
We developed an online survey using the software
Voxco (Acuity 4 Survey, Voxco, Montreal, Canada). The
questionnaire was divided into four parts: 1) general in-
formation on each PHO; 2) information regarding the
use of the molecular typing result up to 2016; 3) infor-
mation on the performance of contact tracing and 4) ex-
pectations for the implementation of a nationwide IMS
of TB. We developed a total of 31 questions. In 19 ques-
tions only one answer was possible, in 11 questions
multiple answers were possible and one question was an
open question. In 10 questions we collected quantitative
information such as the number of TB cases per PHO (for
details about the online survey see the Additional file 1).
The link to the online survey was sent to all 377 PHOs in
Germany on the 24th of April 2017. The responses were
collected at the RKI until the 16th of June 2017. We asked
the PHOs to answer the questions referring to their work
up to the 31.12.2016. The Data Protection Officer
(Datenschutzbeauftragte/r, DSB) and the Information Se-
curity Officer (Informationssicherheitsbeauftragte/r, ISB)
of the RKI examined our study design and gave us their
ethical approval, basis on the fact that there were no data
protection concerns against the implementation of our
study. As our study did not involve interventions no
further ethical clearance was necessary.
Descriptive and analytical approach
We analyzed the response rate country-wide and strati-
fied by German federal state. In addition, we calculated
the molecular typing coverage for each federal state, de-
fined by the number of PHOs which used molecular typ-
ing results divided by the number of invited PHOs per
federal state. We conducted a descriptive analysis of the
answers to the survey. As an analytical approach, we
compared the qualitative answers to the survey between
different groups, specifically between:
1) PHOs that did not use molecular typing results vs.
PHOs that did use molecular typing results;
2) PHOs in the federal state of Baden-Württemberg
vs. PHOs in all other federal states;
3) PHOs that used molecular typing results in 2016 vs.
PHOs that used molecular typing results prior to 2016.
Pearson’s chi-squared and Fisher’s exact tests were
used to determine significant differences in the answers
to the survey between the different groups. Statistical
significance was considered with a two-sided test if
p < 0.05. Data were collected using Microsoft Excel
and analyzed using STATA version 14.0 (Stata Corp.
2011. Stata Statistical Software: Release 12. College
Station, TX: Stata Corp LP).
Results
Survey response rate, number of TB cases and contact
tracings per PHO
A total of 174/377 (46.2%) of PHOs participated in our
online survey. All 16 German federal states were repre-
sented with at least one PHO (Table 1). The molecular
typing coverage varied substantially among the PHOs
belonging to different federal states, ranging from 3.8%
in Rhineland-Palatinate to 54.0% in Baden-Württemberg
and 43.7% in Schleswig-Holstein (Table 1). The median
number of notified TB cases per participating PHO in
2016 was 13.5 (ranging from 0 to 396). The median
number of contact tracings, meaning the number of
individual contacts traced, per PHO in 2016 was 116
(ranging from 2 to 2173). Therefore, for each TB case, a
median of 8.6 contacts were traced.
Descriptive analysis of the survey answers among all
PHOs
A total of 88/377 (23.3%) PHOs used the molecular
typing results in their routine TB surveillance work in
2016 or prior to 2016. The molecular typing was per-
formed in 76/88 (85.2%) cases at the German National
Reference Centre for Mycobacteria (Forschungszentrum
Borstel, Borstel, Germany), in 6/88 (6.8%) cases at other
laboratories, in four cases at multiple places and in two
cases this information was unknown. The most common
molecular typing method analyzed was spoligotyping in
41/88 (46.6%), followed by MIRU in 26/88 (29.5%),
WGS in 7/88 (7.9%) and multiple methods in 14/88
(15.9%). The costs for the molecular typing were covered
by the local PHO in two-thirds of cases (59/88, 67.0%)
or by the laboratory performing the typing (11/88,
12.5%). The estimated median cost for the PHO per
typed isolate was 50 Euro (ranging from 0 to 360 Euro),
considering all the typing methods. The median turn-
around time per isolate, defined as the time taken from
the request to the delivering of the molecular typing re-
sult, was 21 days (ranging from 7 to 90 days, IQR1 = 14,
IQR3 = 28). Among the PHOs that used molecular typ-
ing results, the majority (49/88, 55.7%) did not systemat-
ically document such results in their TB-surveillance
reporting system.
We asked the PHOs: “For which purpose did you use
the molecular typing result?” The most common answer
was “support for epidemiological contact tracing” 62/88
(70.4%), highlighting the added value of combining mo-
lecular typing and epidemiological data in the control of
TB transmission. Among the other purposes, the PHOs
reported: distinguish between reinfection-relapses (18/
88, 20.4%), molecular detection of drug-resistance (10/
88, 11.4%) or detection of false-positive laboratory
results (4/88, 4.5%). We further elaborated on this ques-
tion and asked: “Which were the benefits of using the
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molecular typing results for your work?” The answers of
the PHOs reflected once again the advantages of
combining molecular typing and epidemiological data:
detection of unknown transmission (41/88, 46.6%),
transmission detection over longer time period (37/88,
42.0%), exclusion of previously assumed transmission
(33/88, 37.5%) early detection of outbreaks (25/88,
28.4%) or detection of transregional transmission (24/88,
27.3%). Among the PHOs participating in our survey,
the major barriers to the implementation of the IMS of
TB were: costs (123/174, 70.7%), lack of staff capacity
(57/174, 32.8%) and complex logistics related to sample
shipping (45/174, 25.9%).
A total of 38 PHOs answered that they did not
perceive the IMS of TB as beneficial (or only partially
beneficial, see question 4.1 in the Additional file 2). The
specific reasons for such answers were: “rarity of TB
cases”, “the molecular typing result was not required”
(see below), or “no effect of the molecular typing results
in the practical work”, since the pathway of transmission
of infection was already known due to epidemiological
information.
Comparisons of answers among the different groups of
PHOs
In the Additional file 2, the answers to the survey be-
tween different groups of PHOs are reported. We found
statistically significant differences by comparing local
PHOs that did not use molecular typing results (n = 86)
vs. local PHOs that did use molecular typing results (n
= 88). Indeed, the group that used molecular typing
results perceived it more often as beneficial for their
work compared to the other group (Fig. 1, question 1).
Moreover, the group that did not use the molecular typ-
ing results answered more often that they do not know
if a nationwide IMS of TB will be beneficial for their
routine work (Fig. 1, question 1). The PHOs using mo-
lecular typing results declared also more often that cost
is the major barrier to the implementation of an IMS of
TB (Fig. 1, question 2). The strongest differences be-
tween these two groups were that PHOs using molecular
typing results expected more support and coordination
from regional and national public health institutes such
as the RKI – especially regarding the identification of
molecular clusters (Fig. 1, question 3).
We analyzed the answers of the PHOs in the federal
state of Baden-Württemberg since in this federal state a
pilot study on the feasibility of the IMS was carried out
and we wanted to see their perception about the IMS [20].
The PHOs in the federal state of Baden-Württemberg
responded more positively to the question “will an IMS of
TB be beneficial for your work?” when compared with all
other PHOs (18/23, 78.3% vs. 70/151, 46.4%, p < 0.05).
Another difference between these two groups is that
Table 1 Survey participation and molecular typing rates of local PHO by German federal state










North Rhine-Westphalia 33 53 62.3 15 24.1
Baden-Württemberg 23 37 62.2 20 54.0
Bavaria 22 76 28.9 14 18.4
Lower Saxony 16 44 36.3 7 15.9
Hesse 13 25 52.0 4 16.0
Schleswig-Holstein 12 16 75.0 7 43.7
Brandenburg 11 21 52.4 4 19.0
Thuringia 9 24 37.5 5 20.8
Saxony-Anhalt 8 12 66.7 2 16.7
Unknowna 7 7 100.0 1 14.3
Mecklenburg-Vorpommern 6 8 75.0 2 25.0
Saxony 5 13 38.5 3 23.1
Saarland 5 6 83.4 1 16.7
Berlin 1 1 100.0 0 0.0
Bremen 1 1 100.0 1 100.0
Hamburg 1 7 14.3 1 14.3
Rhineland-Palatinate 1 26 3.8 1 3.8
Total 174 377 46.2 88 23.3
PHO Public health office
a In seven cases, we had no information about the geographical location of the local PHO
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PHOs in Baden-Württemberg expect more support in the
identification of molecular cluster when compared to all
other PHOs (23/23, 100% vs. 87/151, 57.6%, p < 0.05).
Among the PHOs that did use molecular typing
results, we investigated also if there were any changes in
the answers over the time in perception and in expecta-
tions. The PHOs that used molecular typing results in
2016 (n = 39) perceived it as more beneficial for their
work compared to the PHOs that used molecular typing
results prior to 2016 (n = 49) (Fig. 2, question 5). The
PHOs that used the molecular results in 2016 also used
these results for more purposes, such as epidemiological
studies or to verify retrospectively a contact of a TB
index patient (Fig. 2, question 6). In addition, they
perceived also more benefits for their own work, such as
“exclusion of previously assumed transmission”, “early
detection of outbreaks” and “detection of transregional
transmission” (Fig. 2, question 7). We found a difference
also regarding the molecular typing methods analyzed: the
PHOs that used molecular typing results in 2016 analyzed
more often the results of the MIRU molecular typing
method in comparison with the PHOs that used molecu-
lar typing results prior to 2016 (Fig. 2, question 4).
Discussion
In this study, we conducted a survey among the German
local PHOs to assess their use and needs of molecular
typing results for TB surveillance, and their expectations
of an IMS of TB in Germany. These objectives fit within
the broader goal of implementing a nationwide IMS of
TB in Germany.
We observed a high variability in the use of molecular
typing results for TB surveillance among the PHOs in
Germany. We expected such variability since the IMS is
not yet implemented nationally. Around a quarter of the
PHOs invited to our survey used the molecular typing
results in their routine work. The PHOs belonging to
the federal states of Baden-Württemberg and Schleswig-
Holstein have high molecular typing coverages and also
high participation rates to our survey. These high mo-
lecular typing coverages and participation rates might be
explained by the fact that the PHOs in those two federal
states already participated in studies combining molecu-
lar typing results and epidemiological data [5, 19–21].
The stratified analysis on the PHOs belonging to
Baden-Württemberg highlighted a strong positive per-
ception on the implementation of the IMS of TB but
also a need of more support in the identification of
molecular clusters. This outcome might be the conse-
quence of the training and of the support provided by
the RKI and the other collaborators during the pilot
study on the feasibility of the IMS carried out in
Baden-Württemberg between 2008 and 2010 [21]. This
positive outcome of the pilot might have implications
Fig. 1 Answers of local public health offices that did not use vs. did use molecular results. In this figure, only the differences in answers which
were statistically significant between the two groups (p < 0.05) are showed. For an overview of all the possible answers, please refer to the
Additional files 1 and 2. PHO: Public health office; IMS: integrated molecular surveillance; TB: Tuberculosis
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for a successful implementation of the IMS of TB in
Germany.
In our study, we also observed a high variability of the
molecular typing methods used for MTB. The low pro-
portion of WGS observed might be explained by the fact
that some PHOs answering our survey used molecular
typing results also prior to 2016, and therefore they
might not be already updated to the WGS. In addition,
other typing methods might still be cheaper and more
standardized (such as the MIRU) compared to the WGS.
This is true also for the other countries where the IMS
of TB was implemented in the previous years: for ex-
ample in the Netherlands, Slovenia, Sweden and the
United States, the molecular typing method used was
the MIRU [15–18], while in Finland and Denmark the
method used was spoligotyping or IS6110 DNA finger-
print [12, 14]. To our knowledge, England is the only
country where, from March 2017, a routine WGS service
has been implemented for all MTB isolates [23]. How-
ever, a recent survey conducted by the RKI among the
TB National Focal Points in Europe revealed that many
other countries such as Austria, Denmark, Finland
and Norway seem to be in the transition phase to-
wards the implementation of a routine WGS service
(data not shown).
Among the participating PHOs using molecular typing
results, less than half included such results systematically
in their TB surveillance system, which is a prerequisite
to implementing a nationwide IMS of TB. This challenge
can be solved by providing training about the benefits of
the IMS and of the systematic inclusion of the molecular
typing results in the TB surveillance system.
We observed that a third of PHOs that did not use
molecular typing results answered that they did not
know if a nationwide implementation of the IMS of TB
would be beneficial for their work. In addition, several
PHOs answered that they did not perceive the IMS of
TB as beneficial for their routine work. These answers
might reflect the need for training and education on the
benefits of the IMS of TB. The PHOs that used molecu-
lar tying results were indeed more aware of the benefits
of IMS of TB compared to the PHOs that did not use
molecular typing results. We observed a similar trend
between the PHOs that used it in 2016, compared to
those using it prior to 2016. Therefore there seems to be
a growing perception of the benefits of the IMS over
time, and this might be due to several factors: the
growing experience in the interpretation of molecular
typing results, the availability of more advanced and
faster methodologies and the increased education and
Fig. 2 Answers of local public health offices that used molecular results in 2016 vs. prior to 2016. In this figure, only the differences in answers
which were statistically significant between the two groups (p < 0.05) are showed. For an overview of all the possible answers, please refer to the
Additional files 1 and 2. PHO: Public health office; IMS: integrated molecular surveillance; TB: Tuberculosis
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awareness about the IMS of TB. The major benefits
identified by the responding PHOs in our study were the
support in transmission detection, contact tracing and
cluster investigations in outbreaks. Similar results were
obtained also in a study in the Netherlands assessing the
impact of molecular typing on contact tracing [24]. Two
studies in England highlighted also a positive perception
regarding the implementation of an IMS of TB [25, 26].
Indeed, the benefits described in these two studies are
similar to those identified in our study: understanding
TB epidemiology, confirming/refuting suspected trans-
mission or supporting outbreak investigation. Such
benefits can have an impact on public health and save
public health money, for example by avoiding unneces-
sary contacts tracing or by targeting preventive measures
[23, 27]. PHOs using molecular typing results were also
more aware of the barriers, particularly costs, to the
implementation of a nationwide IMS of TB. In addition,
they clearly highlighted their need for more support and
coordination from regional or national public health in-
stitutes, in data interpretation, especially regarding the
support for molecular cluster identification. In our
opinion, this is a clear need identified from the local
PHOs which have direct practical experience with the
molecular surveillance of TB and it will be one of our
main tasks to fulfil this need as national public health
institute.
One of the limitations of our study is that the PHOs
who used molecular typing results might have been
more willing to participate in our survey and to provide
answers, therefore leading to an overestimation of the
use of the molecular typing results. Moreover, prior
experience may have also influenced responses due to
greater insight and education on the value of the IMS in
practice. In addition, PHOs using molecular typing
results in 2016 might also remember more answers and
details compared to the ones that used them prior to
2016. Moreover, we did not ask the PHOs if they ever
received the molecular typing results but they did not
use them. This could have added further insights on the
usefulness of the molecular typing results for the PHOs.
Lastly, around half of the invited PHOs did not partici-
pate in our study, highlighting the need for more train-
ing and awareness on the importance of a national IMS
of TB. Possible reasons to explain why certain PHOs did
not participate in our survey might be the rarity of TB
cases in certain PHOs and also the fact that the molecu-
lar typing result was not part of the official notification,
thus making the PHO less motivated to participate in
such type of survey.
Conclusions
Our study is a step forward in the broader goal of imple-
menting a nationwide IMS of TB in Germany. The
answers of the local PHOs to our survey highlighted
their positive attitude towards the implementation of an
IMS, but also their needs of more support in data inter-
pretation. Therefore, a closer collaboration is needed
between local and national public health authorities. For
example, molecular typing data from different PHOs
should be made more accessible, organized and central-
ized, or regular training workshops on molecular surveil-
lance could be organized. Such closer collaboration
might also encourage and convince those PHOs in
Germany, who do currently not use molecular typing re-
sults in their work, of the benefits of the IMS. In
Germany, the concept of implementing a nationwide
IMS of TB started years ago with smaller and local
molecular surveillance studies–the so-called building
blocks in our introduction–which helped identify spe-
cific needs and room for improvements first at a smaller
scale. After these studies, we are now in a good position
to launch a nationwide IMS of TB. Such an approach
could be used also by other countries, which are on the
way to develop a nationwide IMS of TB.
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